Skip to content

Continuing Care App for Probationers and Parolees

Continuing Care App for Probationers and Parolees With Substance Use Disorders

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04574193
Enrollment
100
Registered
2020-10-05
Start date
2021-03-08
Completion date
2023-02-28
Last updated
2023-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Use Disorders

Brief summary

This project extends successful Phase I work that developed a Continuing Care mobile application (app) for probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration. This Phase II STTR project will finalize app development and evaluate its efficacy in a randomized controlled trial. The project has high public health significance due to its potential to provide an accessible recovery support tool for individuals on probation or parole that could improve their substance use disorder treatment outcomes.

Detailed description

Substance use disorders (SUDs) continue to be one of the most serious public health problems in the US. Studies have consistently documented a substantially higher prevalence of SUDs among adults under criminal justice supervision in the community (i.e., probation or parole) as compared to the general population. There is growing recognition that addiction is a chronic health condition, and individuals with SUDs typically cycle through multiple periods of treatment, abstinence, and relapse over several years to achieve and maintain recovery. Studies show that continuing care interventions can provide ongoing support or extend primary treatment gains with respect to reducing substance use, relapse, and criminal activity. Recent diffusion of Internet and smartphone technologies among disadvantaged populations now offers unprecedented opportunities for increasing access to quality continuing care interventions as well as chronic disease self-management tools. Probationers and parolees at high risk for drug abuse relapse and involvement in health compromising behaviors are an important population that stands to benefit from continuing care technologies. However, to date, no such technologies exist that are specifically tailored to meet the unique needs of this high-risk population. Building on our team's extensive experience in the fields of criminology and substance use, we propose to complete the development of a Continuing Care mobile application (app) and conduct a randomized controlled trial to assess efficacy among clients on probation or parole who are enrolled in outpatient substance use treatment. The app is designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration. It is guided by the principles of the transtheoretical model of behavior change and app content is derived from the Your Own Reintegration System (YOURS) program, an empirically-supported16 intervention that focuses on substance use recovery, reducing criminal thinking and behavior, and managing and building support systems. If proven to be efficacious, the app could be deployed across the national network of outpatient treatment providers, and be highly significant in its direct impact on public health.

Interventions

DEVICEdigital therapeutic for substance use disorders

The Continuing Care application (app) is a HIPAA-compliant, mobile-friendly, software program designed to meet the recovery and personal support needs of probationers and parolees with SUDs who are at elevated risk of relapse, re-arrest, and incarceration.

OTHERTreatment As Usual

12-weeks of weekly group cognitive behavioral therapy

Sponsors

Friends Research Institute, Inc.
CollaboratorOTHER
COG Analytics
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

The evaluation will involve a two-group RCT in which 100 men and women on probation or parole, who are currently receiving outpatient substance use treatment at THC, will be randomly assigned to one of two conditions: (1) Continuing Care app (CC app; n=50): Participants will receive the CC app, in addition to usual care at the treatment program (12-weeks of weekly group cognitive behavioral therapy), or (2) Treatment As Usual (TAU; n=50): Participants will only receive 12-weeks of weekly group cognitive behavioral therapy.

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Age 18 or older * Currently on community supervision (probation or parole) or justice-involvement in the past 12 months * Currently a client receiving outpatient substance use treatment * Willing to receive supplemental treatment services through a mobile app * Willing to provide informed consent and complete research assessments

Exclusion criteria

* Severe psychiatric problems (e.g., untreated psychosis, untreated bipolar disorder) * Suicidality within the past 6-months, as determined by clinical staff, which could make participation in a novel treatment hazardous

Design outcomes

Primary

MeasureTime frameDescription
Weeks Retained in Substance Use Treatmentup to 12 weeksNumber of weeks retained in treatment based on a review of clinical records

Secondary

MeasureTime frameDescription
Completion of Substance Use Treatmentup to 12 weeksTreatment completed (yes or no) based on a review of clinical records
Days of Substance Useup to 18 weeksNumber of days of drug use based on self-report drug use and urine drug screen results
Days of Criminal Activity; Re-arrest; Incarcerationup to 18 weeksNumber of crime days; re-arrest (yes or not); incarceration (yes or no) based on self-report information and public court record databases

Other

MeasureTime frameDescription
Rating of App Satisfactionup to 12 weeksRating of client satisfaction using the app based on self-report information

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026